Does Wegovy Cause Insomnia? Sleep Disturbance, the STEP Program, and the FDA Label

At a glance

• Insomnia is not on the Wegovy label. The Wegovy FDA prescribing information enumerates adverse reactions at the ≥2% threshold (more stringent than the ≥5% threshold used on many labels) and reports no sleep-related adverse event anywhere in the label.
• The STEP-program safety pool was 2,116 patients on Wegovy 2.4 mg vs 1,261 on placebo across four pivotal adult trials. A real insomnia signal at ≥2% incidence in that sample would have been detected.
• SELECT extends the safety database to 17,604 adults followed a median 39.8 months for cardiovascular outcomes. No sleep-related adverse event of special interest emerged in the primary publication, consistent with the label.
• Patient-reported insomnia is real but most plausibly indirect. Three mechanisms account for most reports: GI discomfort fragmenting sleep, sharp evening calorie reduction producing wake-from-hunger episodes, and shifted meal timing disrupting circadian alignment.
• Class-level pharmacovigilance is reassuring for semaglutide. A 2025 disproportionality analysis of FAERS, CVAROD, and DAEN found an insomnia signal for dulaglutide but not for semaglutide or tirzepatide.
• Suicidality risk did NOT increase in the largest real-world cohort. Wang and colleagues 2024 Nature Medicine analyzed >240,000 patients in TriNetX and found semaglutide was associated with a LOWER hazard of suicidal ideation versus comparator anti-obesity and anti-diabetes agents. The Section 5 mood-monitoring language remains, but the population-level signal is negative.
• Red flags warrant prescriber contact. Severe insomnia >2 weeks, new or worsening depressed mood, any new suicidal thoughts, or sleep disruption that does not respond to addressing the three indirect mechanisms all warrant a prompt prescriber call.

What the Wegovy FDA label says about insomnia

The Wegovy prescribing information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b)^[1] reports adverse reactions from a pool of four randomized, placebo-controlled trials in adults with overweight or obesity (the STEP program) that enrolled 2,116 patients on Wegovy 2.4 mg weekly versus 1,261 on placebo. The Section 6.1 Table 3 reporting threshold is set at ≥2% and more frequent than placebo — a more stringent threshold than the ≥5% cutoff used on the Zepbound, Mounjaro, and Ozempic labels. Despite that more sensitive cutoff, no sleep-related adverse event appears.

The full list of labeled ≥2% adverse reactions on Wegovy 2.4 mg in adults: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in T2DM, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, gastroenteritis viral, hair loss, and dysesthesia^[1]. A verbatim search of the complete label for the strings “insomnia”, “somnolence”, “sleep disturbance”, “abnormal dreams”, “dyssomnia”, and “sleep-related” returns zero matches anywhere in Sections 4, 5, 6.1, 6.2 (postmarketing experience), 7 (drug interactions), 8 (use in specific populations), or 17 (patient counseling)^[1]. Insomnia is simply not on the Wegovy label.

The Section 5.7 depression and suicidal-behavior monitoring block does require prescribers and patients to monitor for emergence or worsening of depression, suicidal thoughts, or unusual mood or behavior changes^[1]. Sleep disruption is not enumerated in that section, but it can be a prodromal symptom of mood change and the threshold for prescriber contact should be low when new insomnia is paired with any mood symptom.

The §6.1 Table 3 adverse-reactions data in numbers

The Wegovy ≥2% adverse-reactions table from the pooled STEP-program safety analysis is the cleanest snapshot of which side effects clear the labeled-disclosure threshold. None of them are sleep-related. The dominant cluster is gastrointestinal and the magnitudes are substantially larger than on Ozempic (semaglutide up to 2.0 mg in T2D), reflecting the higher 2.4 mg obesity dose.

The pooled placebo-controlled sample size (2,116 Wegovy, 1,261 placebo) is large enough that a real insomnia signal at the ≥2% reporting threshold would have been detected and enumerated — the table catches events as uncommon as dysesthesia at 2%. The label’s silence on sleep AEs is therefore a meaningful absence rather than a missed signal in an underpowered study or a coarse threshold.

STEP-1 and STEP-2: what the pivotal trials reported

STEP-1 (Wilding and colleagues 2021, NEJM)^[2] randomized 1,961 adults with overweight or obesity and without diabetes 2:1 to semaglutide 2.4 mg or placebo for 68 weeks. The primary tolerability burden was gastrointestinal: nausea in 44.2% of semaglutide patients vs 17.7% on placebo, diarrhea 31.5% vs 15.9%, vomiting 24.8% vs 6.6%, and constipation 23.4% vs 9.5%. The primary publication does not enumerate a sleep-related adverse event in the main safety tables, and the adverse-event reporting categories are inherited by the FDA label discussed above. The full safety appendix likewise does not surface insomnia at a frequency that would have warranted inclusion in Table 3 of the label.

STEP-2 (Davies and colleagues 2021, Lancet)^[3] ran in parallel in 1,210 adults with overweight or obesity and type 2 diabetes for 68 weeks. The GI tolerability profile was similar in magnitude (nausea 34%, diarrhea 22%, vomiting 9% on semaglutide 2.4 mg). Again, no sleep-related adverse event surfaced in the primary publication’s safety tables. The T2D context adds the nocturnal hypoglycemia-monitoring consideration that the Wegovy label flags in Section 5.6 for patients on concomitant insulin or sulfonylurea^[1].

SELECT: 17,604 patients, 39.8 months, no sleep AE signal

SELECT (Lincoff and colleagues 2023, NEJM)^[4] is the largest and longest-duration safety database we have for semaglutide 2.4 mg. The trial randomized 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes to semaglutide 2.4 mg or placebo, with a median follow-up of 39.8 months and a primary endpoint of major adverse cardiovascular events.

The Wegovy label notes that in SELECT, “Safety data collection was limited to serious adverse events (including death), adverse events leading to discontinuation, and adverse events of special interest”^[1]. That design means SELECT was not powered to detect a low-severity insomnia signal that did not lead to discontinuation, but the primary publication and the label both report 16% of WEGOVY-treated patients vs 8% of placebo patients discontinued due to an adverse event — with the discontinuation drivers in the labeled categories (GI events), not a sleep-related cause. Across nearly 60,000 patient-years of semaglutide 2.4 mg exposure, no new sleep-related adverse-event signal of special interest was identified.

Likely mechanisms behind patient-reported insomnia on Wegovy

Three indirect mechanisms account for most patient reports of sleep disruption on Wegovy. Each is biologically plausible, each is most pronounced during the first 4 weeks of treatment and the first week after each dose escalation (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), and each is addressable with practical adjustments rather than requiring drug discontinuation.

Mechanism 1: GI discomfort and nausea fragmenting sleep

Gastrointestinal adverse events are the dominant labeled tolerability burden on Wegovy. STEP-1^[2] reported nausea in 44.2% of patients on semaglutide 2.4 mg vs 17.7% on placebo, with the highest rates during the dose-escalation period. Active nausea and GI discomfort fragment sleep in straightforward ways: difficulty falling asleep while feeling queasy, mid-night awakenings to vomit or pass a bowel movement, and reduced ability to find a comfortable sleeping position when the abdomen is uncomfortable. The relationship is mechanically direct — this is not a subtle effect on sleep architecture but a straightforward arousal from somatic discomfort. For broader management of the GI cluster, see the GLP-1 side effects Q&A hub and the GLP-1 side-effect timeline tool that visualizes the week-by-week adaptation curve.

Mechanism 2: evening calorie reduction and wake-from-hunger

The therapeutic effect of semaglutide 2.4 mg on weight is mediated primarily through appetite suppression and reduced caloric intake. In STEP-1, the 68-week mean body-weight loss was 14.9% on semaglutide vs 2.4% on placebo^[2], via reduced food intake under a modest lifestyle counseling protocol. In practice, many patients respond to the appetite suppression by sharply reducing or skipping the evening meal — the meal where appetite is often lowest because earlier meals have already been satisfying in a way they were not pre-treatment.

Skipping the evening meal entirely can produce a wake-from-hunger pattern in the 2-to-4-AM window. Even in patients without diabetes, overnight glycemic dips into the low-normal range can trigger counter-regulatory responses (cortisol, epinephrine, growth hormone release) that fragment sleep and produce vivid dreams during awakening. In patients with type 2 diabetes on Wegovy plus a sulfonylurea or insulin, the risk of true nocturnal hypoglycemia is more substantial and the Wegovy label flags the interaction in Section 5.6^[1].

The practical pattern: if you are skipping dinner entirely and waking at 2-3 AM, a small protein-forward evening snack (a handful of nuts, a hard-boiled egg, a few ounces of Greek yogurt) often restores continuous sleep without compromising the overall calorie deficit. The goal is glycemic stability across the overnight window, not added daily calories.

Mechanism 3: shifted meal timing disrupting circadian alignment

Sleep and glucose homeostasis are tightly coupled through the circadian system. The 2022 narrative review of sleep and circadian rhythm disturbances in diabetes (Rutters and Nefs, Diabetes, Metabolic Syndrome and Obesity)^[7] summarizes how meal timing acts as a peripheral circadian zeitgeber: meals consumed at consistent times synchronize hepatic and adipose-tissue circadian clocks with the central suprachiasmatic clock that drives sleep-wake rhythms. Disrupting the meal schedule disrupts the alignment.

Semaglutide 2.4 mg commonly shifts the meal pattern away from the pre-treatment baseline. Patients describe eating less in the evening, eating earlier in the day, occasionally skipping breakfast (because appetite has not yet recovered from the previous evening), and consolidating intake into one or two eating windows rather than three regular meals. Any of these shifts changes the timing signal the peripheral clocks receive and can produce a transient period of circadian misalignment until a new stable pattern is established — experienced as difficulty falling asleep at the usual time, waking unusually early, or daytime sleepiness without obvious cause.

The mitigation is to anchor at least one regular eating time each day — ideally a consistent morning meal, even a small one — rather than allowing all meal timing to drift with appetite. Consistent meal anchors are a well-established chronobiology lever for re-aligning peripheral clocks.

Class-level pharmacovigilance: Katranski 2025 FAERS analysis

The 2025 disproportionality analysis by Katranski and colleagues in the International Journal of Clinical Pharmacy^[6] examined psychiatric adverse-event reports across the US FAERS, Canadian CVAROD, and Australian DAEN pharmacovigilance databases for all approved GLP-1 analogues. The analysis found a significant insomnia signal for dulaglutide (FAERS reporting odds ratio 2.93, 95% CI 2.35-3.66) but did not identify a corresponding insomnia signal for semaglutide or tirzepatide in its published results.

That null finding for semaglutide is consistent with the Wegovy label being silent on sleep AEs and supports the framing that semaglutide is not a direct insomnia-causing drug at the pharmacological level. The dulaglutide signal is worth noting for patients who have been on Trulicity and are switching to Wegovy — the molecule-specific pharmacology differs, and a patient with a personal history of insomnia on dulaglutide cannot assume the same pattern will recur on semaglutide.

Suicidality: the Wang 2024 Nature Medicine null finding

The semaglutide suicidality question got significant media attention in 2023 after the European Medicines Agency opened an investigation following individual case reports. The largest real-world cohort study to address the question is Wang and colleagues 2024 in Nature Medicine^[5], which analyzed >240,000 patients in the TriNetX electronic health record network comparing semaglutide users to users of non-GLP-1 anti-obesity and anti-diabetes agents. The headline result: semaglutide was associated with a lower hazard ratio of first-time and recurrent suicidal ideation versus comparator agents.

That negative population-level signal does not eliminate individual risk. The Wegovy label Section 5.7 continues to require prescriber and patient monitoring for emergence or worsening of depression, suicidal thoughts, and unusual changes in mood or behavior^[1]. Sleep disruption is not itself a labeled mood signal, but it can be prodromal, and any patient with new or worsening insomnia accompanied by depressed mood should contact the prescriber promptly. Any new suicidal thoughts are an immediate prescriber contact and, in the US, an immediate 988 call or text to the Suicide and Crisis Lifeline.

How Wegovy compares to Zepbound, Mounjaro, and Ozempic on sleep AEs

The picture is consistent across the GLP-1 / GIP-GLP-1 class labels: insomnia is not enumerated at the labeled reporting threshold on Wegovy, Ozempic (also semaglutide, up to 2.0 mg), Zepbound (tirzepatide), or Mounjaro (also tirzepatide). The Wegovy threshold is the most sensitive at ≥2% — the Zepbound and Ozempic tables use ≥5% — so Wegovy is actually the strongest test of the “does GLP-1 cause insomnia” question, and the answer at ≥2% is still no. For a deeper read on the side-by-side picture, see the sister articles Zepbound insomnia and sleep disturbance evidence and Ozempic insomnia and sleep disturbance evidence, along with the trial-level What the trials actually showed: GLP-1 side effects review and the head-to-head Zepbound vs Wegovy side-effects comparison.

Why this matters for the Wegovy insomnia question: the Katranski 2025 dulaglutide finding^[6] proves the class is not monolithic at the pharmacovigilance level — molecule-specific pharmacology does differ. The semaglutide-specific null on insomnia is therefore meaningful rather than a generic class-effect assumption.

When insomnia is a red flag on Wegovy

The Wegovy label Section 5.7 carries the GLP-1-class depression and suicidal-behavior monitoring guidance^[1]: prescribers and patients are instructed to monitor for the emergence or worsening of depression, suicidal thoughts, and unusual changes in mood or behavior. New or worsening insomnia is a non-specific symptom but can be one of several prodromal mood-symptom signals, and the threshold for prescriber contact should be low when sleep disruption is accompanied by any of the following:

• New or worsening depressed mood, hopelessness, or loss of interest — particularly if these symptoms emerged after starting or escalating the dose.
• Any new suicidal thoughts, plans, or self-harm urges — this is an immediate prescriber contact and, in the presence of plan or intent, an immediate emergency-services contact (call or text 988 in the US for the Suicide and Crisis Lifeline).
• Severe insomnia for more than 2 weeks — defined as taking more than 30 minutes to fall asleep on most nights, or being awake for more than 30 minutes mid-night on most nights, with daytime functioning impairment.
• Sleep disruption that does not respond to addressing the three indirect mechanisms above (GI symptoms managed, regular evening protein-forward snack, consistent meal-time anchor) over a 2-to-4-week observation window.
• New or worsening daytime sleepiness in the OSA-risk profile (obesity, snoring history, witnessed apneas) — this warrants a sleep-study referral regardless of the Wegovy context, since untreated OSA is one of the more common reversible causes of fragmented sleep.
• Symptoms consistent with acute pancreatitis or gallbladder disease — severe persistent abdominal pain (with or without radiation to the back) that disrupts sleep is a Section 5.2 and 5.3 red flag and requires immediate prescriber contact and discontinuation pending evaluation.

Practical sleep hygiene during Wegovy titration

For patients in the first 4 weeks of Wegovy or in the 5-to-7-day window after a dose escalation (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a few practical adjustments address most of the patient-reported sleep-disruption pattern without requiring drug discontinuation:

• Time the weekly injection earlier in the day rather than evening. Semaglutide’s ~7-day half-life makes within-week timing essentially flat at steady state, but the first 24-48 hours after the injection are when peak GI tolerability challenges occur. Injecting in the morning of a low-demand day (many patients pick a Saturday or Sunday morning) keeps the worst tolerability hours away from the sleep window.
• Eat a small, protein-forward evening snack if you skipped dinner. A handful of nuts, a hard-boiled egg, a small Greek yogurt, or a turkey roll-up 1-2 hours before bed addresses the wake-from-hunger mechanism. The total calorie addition is small (100-200 kcal) and does not meaningfully blunt the overall calorie deficit.
• Anchor one consistent meal time per day. A morning meal at a consistent time — even a small one — reinforces the peripheral circadian alignment that drifting meal patterns disrupt. Coffee plus a small protein-forward item works for most patients.
• Skip evening alcohol during the diagnostic period. Alcohol on top of altered gastric emptying is a common unrecognized driver of fragmented sleep on Wegovy. A 2-to-3-week alcohol-free observation is the highest-yield first intervention.
• Hydrate during the day, not the evening. Front-loading water intake to the first 8-10 waking hours reduces mid-night urination while still addressing the dehydration risk flagged in Wegovy Section 5.5^[1] for patients with significant GI events.
• Track fatigue separately from sleep quality. Daytime fatigue on Wegovy (a labeled ≥2% adverse reaction at 11% on the 2.4 mg dose^[1]) is a distinct phenomenon from sleep disruption and has its own mechanisms (caloric deficit, electrolyte shifts, dehydration). The Wegovy fatigue causes and management evidence review covers that side of the picture.
• Standard sleep hygiene applies. Consistent bedtime, cool dark room, screens off 30-60 minutes before bed, no caffeine after early afternoon. None of these are Wegovy-specific, but the early-treatment window is a poor time to ignore the basics.

How this fits the broader Wegovy side-effect picture

Insomnia sits in an unusual position relative to the rest of the Wegovy side-effect cluster: the FDA label is silent on sleep AEs across Sections 4, 5, 6, 7, and 17 at a more sensitive ≥2% threshold than most GLP-1 labels use, but the patient-reported signal in online communities is persistent enough that ignoring it would be dishonest. The most defensible framing is the one that respects both the trial evidence and the patient experience: the registrational STEP-program data, the long-duration SELECT safety database, and the Katranski 2025 pharmacovigilance analysis all provide no support for a direct pharmacological insomnia effect at clinically used doses of semaglutide 2.4 mg, but the drug reliably produces three downstream changes (GI discomfort, evening calorie reduction, meal-timing shifts) each of which can plausibly disrupt sleep through mechanisms that the trial framework was not designed to capture.

Verdict

Insomnia is not listed anywhere in the Wegovy FDA prescribing information — not in Section 6.1 Adverse Reactions at the ≥2% threshold, not in Section 5 Warnings and Precautions, not in Section 17 Patient Counseling. The pooled STEP-program safety database (N=2,116 Wegovy 2.4 mg vs 1,261 placebo) catches adverse events down to 2% incidence and reports zero sleep-related events. The SELECT trial extends the safety record to 17,604 patients followed a median 39.8 months without surfacing a sleep-related signal of special interest. The Katranski 2025 disproportionality analysis of FAERS, CVAROD, and DAEN found no insomnia signal for semaglutide (the signal it did find was for dulaglutide).

Patient reports of difficulty falling asleep and fragmented mid-night awakenings are real but most plausibly mediated by three indirect mechanisms: GI nausea and discomfort, sharp evening calorie reductions producing wake-from-hunger episodes, and shifted meal-timing patterns disrupting circadian alignment. For most patients, sleep disruption on Wegovy is time-limited, peaks during the first 4 weeks and after dose escalations, and responds to practical adjustments: morning injections, a small evening protein-forward snack, consistent meal-time anchors, and skipping evening alcohol during a 2-to-3-week diagnostic period. Severe insomnia lasting more than 2 weeks, sleep disruption that does not respond to those adjustments, or any sleep symptom accompanied by new or worsening depressed mood warrants prompt prescriber contact under the Section 5.7 mood-monitoring guidance. Any new suicidal thoughts are an immediate prescriber contact and, in the US, an immediate 988 call or text.

This article is educational and does not constitute medical advice. Decisions about Wegovy dosing, timing, and management of sleep symptoms should be made with the prescribing clinician, particularly for patients with type 2 diabetes on insulin or a sulfonylurea, a history of mood disorder, or severe or persistent sleep disruption.